<code id='DA6B1D6987'></code><style id='DA6B1D6987'></style>
    • <acronym id='DA6B1D6987'></acronym>
      <center id='DA6B1D6987'><center id='DA6B1D6987'><tfoot id='DA6B1D6987'></tfoot></center><abbr id='DA6B1D6987'><dir id='DA6B1D6987'><tfoot id='DA6B1D6987'></tfoot><noframes id='DA6B1D6987'>

    • <optgroup id='DA6B1D6987'><strike id='DA6B1D6987'><sup id='DA6B1D6987'></sup></strike><code id='DA6B1D6987'></code></optgroup>
        1. <b id='DA6B1D6987'><label id='DA6B1D6987'><select id='DA6B1D6987'><dt id='DA6B1D6987'><span id='DA6B1D6987'></span></dt></select></label></b><u id='DA6B1D6987'></u>
          <i id='DA6B1D6987'><strike id='DA6B1D6987'><tt id='DA6B1D6987'><pre id='DA6B1D6987'></pre></tt></strike></i>

          entertainment

          entertainment

          author:explore    Page View:367
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          NIH tests clinical research in primary care with $30 million program
          NIH tests clinical research in primary care with $30 million program

          TheNIH'snewprimarycareresearchnetworkaimstoimproverepresentationinclinicalscience.AdobeFormanyAmeric

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Statins may not be needed by millions of people, study suggests

          AnewanalysissuggeststhatfarfewerAmericanswouldbecandidatesforcholesterol-loweringdrugstopreventcardi